The Cigna Group (CI) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $10.28B | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.60× | Operating cash flow / net income. Period ending 2026-06-30. $10.28B ÷ $6.42B ≈ 1.60× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 10.28B USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 282.38B USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 6.42B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $10.28B | (m) | (m) | $282.38B | (m) | $6.42B | (m) | (m) | (m) | 1.60× |
| 2026-03-31 | (m) | (m) | $8.81B | (m) | (m) | $277.89B | (m) | $6.29B | (m) | (m) | (m) | 1.40× |
| 2025-12-31 | (m) | (m) | $9.60B | (m) | (m) | $274.90B | (m) | $5.96B | (m) | (m) | (m) | 1.61× |
| 2025-09-30 | (m) | (m) | $8.66B | (m) | (m) | $268.08B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $5.29B | (m) | (m) | $262.02B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $7.44B | (m) | (m) | $255.37B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $10.36B | (m) | (m) | $247.12B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $6.62B | (m) | (m) | $232.59B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $9.40B | (m) | (m) | $217.94B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $11.63B | (m) | (m) | $206.00B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $11.81B | (m) | (m) | $195.26B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $12.45B | (m) | (m) | $189.90B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $12.90B | (m) | (m) | $186.13B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $11.65B | (m) | (m) | $183.03B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $8.66B | (m) | (m) | $180.52B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $10.83B | (m) | (m) | $180.45B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $9.67B | (m) | (m) | $179.46B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $8.13B | (m) | (m) | $177.11B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $7.19B | (m) | (m) | $174.08B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $7.21B | (m) | (m) | $170.10B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $5.99B | (m) | (m) | $166.77B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $9.56B | (m) | (m) | $162.90B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $10.35B | (m) | (m) | $160.40B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $8.85B | (m) | (m) | $156.93B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $10.41B | (m) | (m) | $154.53B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $8.18B | (m) | (m) | $154.09B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $8.44B | (m) | $9.48B | $1.05B | (m) | $153.57B | (m) | (m) | (m) | (m) | 5.49% | (m) |
| 2019-09-30 | $5.90B | (m) | $6.82B | $922.00M | (m) | $129.62B | (m) | (m) | (m) | (m) | 4.55% | (m) |
| 2019-06-30 | $4.18B | (m) | $4.98B | $805.00M | (m) | $102.52B | (m) | (m) | (m) | (m) | 4.07% | (m) |
| 2019-03-31 | $4.32B | (m) | $4.94B | $619.00M | (m) | $75.18B | (m) | (m) | (m) | (m) | 5.74% | (m) |
| 2018-12-31 | $3.24B | (m) | $3.77B | $528.00M | (m) | $48.65B | (m) | (m) | (m) | (m) | 6.66% | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $44.98B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $43.90B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $42.79B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $3.62B | (m) | $4.09B | $471.00M | (m) | $41.81B | (m) | (m) | (m) | (m) | 8.65% | (m) |
| 2016-12-31 | $3.56B | (m) | $4.03B | $461.00M | (m) | $39.84B | (m) | (m) | (m) | (m) | 8.95% | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health, Inc. (ELV) | United States | $86.364B | 16.90 |
| HUMANA INC (HUM) | United States | $45.651B | 18.44 |
| CENTENE CORP (CNC) | United States | $30.588B | -6.22 |
| MOLINA HEALTHCARE, INC. (MOH) | United States | $10.091B | -1,697.50 |
| Alignment Healthcare, Inc. (ALHC) | United States | $1.593B | 121.28 |
| TRUPANION, INC. (TRUP) | United States | $0.984B | |
| UNITEDHEALTH GROUP INC (UNH) | United States | $336.652B | 26.62 |